To evaluate the impact of adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma and lymphovascular invasion (LVI) after radical nephroureterectomy (RNU).
INTRODUCTION
Upper tract urothelial carcinoma (UTUC) is a rare malignancy, with a reported annual incidence in the Western literature of 2 per 100,000 persons [1] . Despite Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy Lee Although advanced UTUC is associated with poor oncologic outcomes, there is no standardized therapy conf erring a survival benef it af ter radical nephro ureterectomy (RNU). Currently, no randomized trials that have investigated the role of adjuvant chemotherapy (AC) for UTUC exist, and there is insufficient evidence to integrate neoadjuvant chemotherapy or AC into a treatment strategy for advanced UTUC. The majority of the available data are from retrospective analyses and the results have been inconclusive [36] . A recent meta analysis showed that cisplatinbased AC was beneficial in terms of overall survival (OS) and diseasespecific survival; however, the results were also limited by the relatively small sample size and the retrospective nature of the studies included in the analysis [7] .
Numerous studies have investigated prognostic factors in patients with UTUC, and tumor stage and tumor grade have been reported to be the most significant prognostic factors [35] . In addition, lymphovacular invasion (LVI) has been demonstrated as a predictor of poor prognosis in several studies [814] . Moreover, the latest European guidelines on UTUCs suggested LVI as an independent predictor of survival [15] . In our previous study, we also reported that LVI was a significant prognostic factor for recurrencefree and cancerspecific survival (CSS) in patients with UTUC [9] . In this study, we extended our previous UTUC cohort and investigated whether AC improved survival in patients with UTUC and LVI.
MATERIALS AND METHODS
Patient inf ormation was retrospectively collected f rom a database approved by the Yonsei University Institutional Review Board. A review of medical records of our institute identified 552 patients with primary UTUC who underwent RNU between 1986 and 2013. We excluded 181 patients who had incomplete data on LVI and 27 patients treated with neoadjuvant chemotherapy. Thus, a total of 344 patients were included in our study.
Each patient underwent preoperative evaluation, including blood test, urine cytology, cystoscopy, chest xray, abdominopelvic computed tomography, and bone scan. Clinicopathological variables including age, gender, tumor stage, tumor grade, tumor location, and LVI status were investigated.
All surgical specimens were analyzed by uropathologists of our institution. Tumor grades were assessed according to the 1998 World Health Organization/International Society of Urologic Pathology consensus classification [16] .
Staging was performed according to the American Joint Committee on Cancer system [17] . LVI was defined as the unequivocal presence of cancer cells in endotheliumlined lymphatic and vascular channels without underlying muscular walls [18] . Routine light microscopic examination with hematoxylin and eosin was performed; no immuno histochemical staining was used to identify LVI.
Postoperative followup was performed every 3 months for 2 years, and then every 6 months thereafter. Followup included history, physical examination, serum chemistry studies, urinary cytology, chest radiography, cystoscopic evaluation of the bladder, and radiographic evaluation of the contralateral upper urinary tract.
The cause of death was corroborated by reviewing the charts. Death certificates were used to assess cause of death.
Patients treated with at least one cycle of chemotherapy within 3 months af ter RNU were regarded to have received AC based on pathological stage pT3 or greater or node positivity. Two types of platinumbased chemo therapies were used: methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin (MVAC) or gemcitabine and cisplatin (GC). Cisplatin was substituted with carboplatin if the glomerular filtration rate was between 30 and 49 mL/min. The treatment protocols and followup schedules were surgeondependent. There was no routine restaging postoperatively before AC.
Patients were stratified into two groups in accordance with the presence of LVI, and clinicopathological features were compared between the two groups. Qualitative variables were compared by using a chisquare test and quantitative variables were compared by using Student ttest. The prognostic significance of LVI was examined in the entire cohort and we also evaluated whether AC was independently associated with OS and CSS in accordance with the presence of LVI. Univariate and multivariate Cox's proportional hazard regression models were used to identify the independent parameters associated with OS and CSS.
All reported pvalues were twosided, and a pvalue of ≤0.05 was considered to indicate statistical significance. All statistical tests were carried out with IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA).
RESULTS
Patients were divided into two groups according to the presence of LVI: group 1 (n=86, LVI (+)) and group 2 (n=258, LVI (-)). Patients with LVI were significantly older and
The impact of LVI on adjuvant chemotherapy in UTUC had higher pathologic stage and tumor grade ( Table  1 ). The 5year OS and CSS rates were 31.0% and 45.0%, respectively. OS and CSS were lower in patients with LVI than in patients without LVI (p<0.001, Fig. 1A ; p<0.001, Fig.  1B , respectively).
Of the 344 patients, 64 (18.6%) received AC and 280 (81.4%) were treated with surgery alone. Also, LVI was independently associated with worse CSS and OS after adjustment for age, gender, pathologic stage, and tumor grade. In the entire cohort, AC was not independently associated with survival (CSS, p=0.161; OS, p=0.144) ( Table  2 ). In patients with LVI (group 1), AC was independently associated with improved CSS (hazard ratio [HR], 0.51; p=0.027) and OS (HR, 0.50; p=0.025) after adjustment for other variables (Table 3 ). In patients without LVI (group 2), AC was not significantly associated with survival and had no impact on CSS or OS (Table 3) .
Patients with LVI were further stratified by patho logical stage (pT12 vs. pT34) and we further evaluated the impact of AC. A favorable impact of AC on CSS and OS was found in patients with pT34 and LVI but not in patients with pT12 and LVI in the univariate Cox's proportional hazard regression analyses (Table 4 ). In patients with pT34, AC was not significantly associated with CSS or OS in the univariate or multivariate analysis (data not shown).
DISCUSSION
We analyzed clinicopathologic features and survival outcomes of patients treated with RNU for UTUC over two decades. AC was not significantly associated with CSS or OS in all patients. However, AC was independently associated with CSS and OS in patients with LVI. Specifically, there was a significant difference in survival after AC in patients with T34 and LVI but not in those with T12 and LVI.
There is no standardized chemotherapy conferring a survival benefit after RNU. Although UTUC is similar morphologically to lower tract urothelial carcinoma, there are occasional phenotypic and genotypic differences [7] . Therefore, these f indings suggest a dif ference in chemotherapy response between UTUC and lower tract urothelial carcinoma. Nevertheless, many clinicians treat patients with highrisk UTUC with AC. Several platinum based regimens have been proposed, although AC protocols are not standardized. The efficacy of platinumbased AC was expected to be similar to that seen in bladder cancer because of similarities in the pathological features. Clinical decisionmaking regarding AC is dependent on multiple factors such as performance and impaired renal function after RNU. Urologists should consider that most patients with AC underwent cisplatinbased chemotherapy with nephrotoxicity.
The prospective randomized controlled perioperative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) trial has enrolled patients with UTUC staged pT2pT4 N03 M0 or pTany N13 M0 after RNU starting in 2012 [17] . Until the results of the POUT trial are revealed, the efficacy of AC after RNU will remain controversial. However, although there is no wellpowered level 1 evidence to support AC for advanced UTUC, several studies have examined the role of AC. Kwak et al. [3] suggested that in a multivariable Cox proportional hazard analysis of 43 patients with UTUC, AC was strongly associated with OS. Another recent study reported that cisplatinbased AC for UTUC had no influence on CSS; however, AC can reduce bladder recurrence [4] . Lucca et al. [6] showed that only patients at the highest risk for disease recurrence with pT3/T4 N+ disease may benefit from AC. A recent retrospective analysis suggested that AC had no survival benefit for CSS and OS in patients with advanced UTUC (pT3N0, pT4N0, and/or lymph node positive) [5] .
Our study showed that there was no signif icant dif ference in CSS or OS between an AC group and a no-adjuvantchemotherapy group. However, this study presents a favorable response to AC in patients with LVI+ The impact of LVI on adjuvant chemotherapy in UTUC and pT3pT4N0/x. A recent metaanalysis investigating AC for UTUC found an OS and diseasefree survival benefit among patients treated with cisplatinbased AC compared with those who had surgery alone [7] . Established studies have shown that AC is not significantly associated with outcomes of patients with lymphnodepositive disease. We found that AC was effective in patients with highrisk UTUC and LVI. AC reduced the relative risk of UTUC related CSS by 50% (HR, 0.50; p=0.025). However, these studies suffer from selection biases in which highrisk patients are selected to receive AC compared with their counterparts who undergo observation. Several studies have reported that LVI is a significant prognostic factor in patients with UTUC as well as other urologic malignancies. Recent studies reported the significance of LVI for bladder cancer. LVI was strongly associated with lymph node invasion because of the presence of circulating cancer cells and the formation of micrometastasis, which suggested LVI as a predictor of poor prognosis [8, 19] . Our previous study reported that LVI was significantly associated with recurrence free survival or CSS in patients who had only localized UTUC (pTa3N0M0) [9] . This study showed that LVI was independently associated with worse CSS and OS after adjustment for age, gender, pathologic stage, and tumor grade. A metaanalysis confirmed that patients with LVI were associated with LN metastases and suggested an opportunity for identifying patients for AC.
Hurel et al. [11] showed that the incidence of LVI (+) was slightly higher (29.6%) than previously described, because they did not classify unknown LVI status as LVI (-). In pathologic reports, LVI status was not routinely described. In previous studies, LVI was detected in -15% to 20% of cases [10] . In our study, we excluded patients without LVI status in pathologic reports. The incidence of LVI (+) was 25.0%.
This study had limitations. Several characteristics could account for the heterogeneity in the results, including the small size cohort, the multiple physicians, and the variability of intraoperative management. Heterogeneity of patients treated with AC existed. Multiple factors inf luenced the clinical decision making regarding the use of AC such as age, performance status, and renal function. Although AC regimens in the study cohort were not standardized, cisplatinbased chemotherapy was used for the standard AC regimen. We analyzed the impact of AC by including all 3 regimens and comparison between regimens was not performed.
Another limitation was the extent of lymph node dissection. pN stage and lymph node dissection may influence the decisionmaking regarding AC. However, in our study, regional lymph node dissection was not routinely performed in patients with clinically apparent lymphadenopathy on preoperative radiologic imaging or lymphadenopathies found intraoperatively.
Finally, the practice to demonstrate LVI status was performed only for select cases suspicious for invasion across the study period. Although the patients without LVI status were excluded and our incidence of LVI is similar to previous results, the potential for selection bias exists.
Despite the limitations of our study, we demonstrated that AC improved oncologic outcomes in patients with LVI who underwent RNU for UTUC. We expect a large, prospective randomized investigation to verif y our conclusions.
CONCLUSIONS
In the current study, LVI and pT stage were signi ficant prognostic factors for CSS and OS in patients with UTUC. The subgroup of patients with T34 and LVI is the target population for AC.
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